Back to baked potato? Or is it another "laboratory finding"?
Amgen, Genentech and City of Hope: is it about money or principles?
Medical meetings: a limit is needed, but Italian legislators have exaggerated
Advanced pancreatic cancer-5 years on
Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled?
Heating the patient: a promising approach?
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma
Whole-body hyperthermia (41.8°C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
Management of women with ductal carcinoma in situ of the breast: a population-based study
Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study
Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study
Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement
Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs
Assessment of the risk/benefit ratio of phase II cancer clinical trials by Institutional Review Board (IRB) members
Exacerbation of oxaliplatin neurosensory toxicity following surgery
Adjuvant interferon for melanoma
Adjuvant interferon for melanoma
Planning palliative or terminal care: the dilemma of doctors' prognoses in terminally ill cancer patients
Prediction of survival in terminally ill cancer patients: why we cannot avoid an evidence-based palliative medicine
Cancer Chemotherapy and Biotherapy: Principles and Practice